logo
  Join        Login             Stock Quote

Astrazeneca (AZN) Launches Dutoprol Tablets In U.S. To Treat High Blood Pressure

 April 12, 2012 10:13 AM
 


AstraZeneca Plc (NYSE:AZN) said it launched Dutoprol tablets for treatment of high blood pressure in the U.S.

The Dutoprol tablets is the first and only once-daily antihypertensive agent that contains the active ingredient of Toprol-XL (metoprolol succinate) plus a low-dose diuretic (also known as a water pill) that provides proven blood pressure lowering at 24 hours.

Instead of a traditional payer contracting strategy, AstraZeneca has taken a novel approach in launching Dutoprol at a wholesale acquisition price ($15.90) that's competitive to the generics of Toprol-XL and hydrochlorothiazide tablets, with or without insurance coverage.

[Related -Forest Laboratories, Inc. (NYSE:FRX): Should Astrazeneca Plc Buy Forest Labs?]

The company said about 36% of the patients treated with high blood pressure remains uncontrolled and Dutoprol may provide another treatment option for patients with hypertension.

AstraZeneca has created Dutoprol Direct, a direct-to-patient mail-order program, which may offer additional savings to patients beyond the retail pharmacy price so they can fill their prescription for $18.33 per month, with free shipping and handling, when they order a 90-day supply.

However, for patients who wish to use their local pharmacies, AstraZeneca has also created a retail pharmacy program.

With Dutoprol, AstraZeneca builds upon the hypertension legacy of Toprol-XL, which has been in use for 20 years as a treatment for hypertension and was among the nation's top-ten most-prescribed medicines for the five years prior to the introduction of generic versions of Toprol-XL at all dosage strengths.

[Related -Merger Arbitrage Mondays – June 3, 2013]

Dutoprol is approved to lower high blood pressure, which helps in reducing the risk of certain heart-related problems such as stroke and heart attack.

Hypertension, or high blood pressure, is dangerous because it makes the heart work too hard and contributes to atherosclerosis (hardening of the arteries). It increases the risk of heart disease and stroke, which are the first and third leading causes of death among Americans. High blood pressure can also result in other conditions, such as congestive heart failure, kidney disease, and blindness.

AZN is trading up 0.18% at $44.50 on Thursday. The stock has been trading between $40.89 and $52.54 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageSector Detector: Bulls Go Down Swinging, Refusing To Give Up Much Ground

Although the stock market displayed weakness last week as I suggested it would, bulls aren’t going down read on...

article imageThe Bumpy Road Ahead To Policy Normalization

When the dust clears from tomorrow’s Fed announcement, the crowd’s expecting that the slow but persistent read on...

article imageAnalyzing Performance Histories That Might Have Been

The trend in recent years of securitizing more of the world’s market betas offers investors, in theory, read on...

article imageBig Prints in VIX Calls

The CBOE Vix Index is in positive territory on Friday morning as shares in the S&P 500 Index move slightly read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.